Trials / Unknown
UnknownNCT04369482
Posterior Capsule Opafication of Different Hydrophobic Acrylic Intraocular Lenses: Vivinex iSert P261 vs.Clareon IOL
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 40 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
On the day of surgery, the first eye to be operated is randomised to receive a Vivinex , HOYA Surgical Optics GmbH or an Clareon, Alcon, Fort Worth, Texas. The second eye to be operated receives the other IOL type. A complete biomicroscopic examination, visual acuity testing using autorefractometer, contrast sensitivity testing, and standardised retroillumination photography for PCO evaluation, will be performed 6 month (30-60 days), 1.5 years (± 3 months) and 3 (± 3 months) years postoperatively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Alcon Clareon | Implantation of an intraocular lens Alcon Clareon |
| DEVICE | Hoya Vivinex | Implantation of an intraocular lens Hoya Vivinex |
Timeline
- Start date
- 2019-01-01
- Primary completion
- 2022-12-01
- Completion
- 2023-02-01
- First posted
- 2020-04-30
- Last updated
- 2022-05-17
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT04369482. Inclusion in this directory is not an endorsement.